SG10201701323TA - Antibodies to ccr2 - Google Patents

Antibodies to ccr2

Info

Publication number
SG10201701323TA
SG10201701323TA SG10201701323TA SG10201701323TA SG10201701323TA SG 10201701323T A SG10201701323T A SG 10201701323TA SG 10201701323T A SG10201701323T A SG 10201701323TA SG 10201701323T A SG10201701323T A SG 10201701323TA SG 10201701323T A SG10201701323T A SG 10201701323TA
Authority
SG
Singapore
Prior art keywords
ccr2
antibodies
Prior art date
Application number
SG10201701323TA
Other languages
English (en)
Inventor
Ronald P Gladue
Bradley T Keller
Shinji Ogawa
Arvind Rajpal
Laurie A Tylaska
Shelley Sims Belouski
Larry L Green
Meina Liang
Original Assignee
Amgen Fremont Inc
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc, Pfizer filed Critical Amgen Fremont Inc
Publication of SG10201701323TA publication Critical patent/SG10201701323TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
SG10201701323TA 2008-08-18 2009-08-17 Antibodies to ccr2 SG10201701323TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18935708P 2008-08-18 2008-08-18

Publications (1)

Publication Number Publication Date
SG10201701323TA true SG10201701323TA (en) 2017-04-27

Family

ID=41347729

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013063318A SG193216A1 (en) 2008-08-18 2009-08-17 Antibodies to ccr2
SG10201701323TA SG10201701323TA (en) 2008-08-18 2009-08-17 Antibodies to ccr2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013063318A SG193216A1 (en) 2008-08-18 2009-08-17 Antibodies to ccr2

Country Status (22)

Country Link
US (2) US8710191B2 (xx)
EP (1) EP2321351B1 (xx)
JP (1) JP5685535B2 (xx)
KR (1) KR101772706B1 (xx)
CN (1) CN102239180B (xx)
AU (1) AU2009283199B2 (xx)
BR (1) BRPI0916973A2 (xx)
CA (1) CA2734578C (xx)
CO (1) CO6351802A2 (xx)
DK (1) DK2321351T3 (xx)
ES (1) ES2658117T3 (xx)
HK (1) HK1163134A1 (xx)
IL (1) IL211284A (xx)
MX (1) MX2011001911A (xx)
MY (1) MY160892A (xx)
NO (1) NO2321351T3 (xx)
NZ (1) NZ591471A (xx)
PE (1) PE20110774A1 (xx)
RU (1) RU2547595C2 (xx)
SG (2) SG193216A1 (xx)
WO (1) WO2010021697A2 (xx)
ZA (1) ZA201101047B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116299A2 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
US20110038871A1 (en) * 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
EP3539987A1 (en) 2011-01-10 2019-09-18 NovImmune S.A. Anti-tlr4 antibodies and methods of use thereof
CN102603649B (zh) * 2011-01-20 2016-05-25 赣南师范学院 一种以地巴唑为先导分子的荧光探针化合物及其制备方法
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
WO2012172339A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory arthritis
WO2012172343A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating primary sclerosing cholangitis
DK2717940T3 (da) 2011-06-13 2020-07-13 Tla Targeted Immunotherapies Ab Behandling af tilstande associeret med metabolisk syndrom
ES2637390T3 (es) 2011-06-13 2017-10-13 Tla Targeted Immunotherapies Ab Tratamiento de afecciones respiratorias
WO2012172336A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
EP2718311B1 (en) 2011-06-13 2018-01-17 TLA Targeted Immunotherapies AB Treating multiple sclerosis
WO2012172337A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cardiovascular disease
ES2688081T3 (es) 2011-06-13 2018-10-30 Tla Targeted Immunotherapies Ab Tratamiento de dolencias asociadas a septicemia
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
US20140349321A1 (en) * 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
EP2864358B1 (en) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2016081801A1 (en) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Use of an anti-ccr2 antagonist in the treatment of an infectious disease
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3262418B1 (en) 2015-02-26 2019-05-01 Innovative Concepts in Drug Development Diagnostic markers of cognitive impairments, kits and uses thereof
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
HUE060258T2 (hu) 2016-05-02 2023-02-28 Prothena Biosciences Ltd Tau immunterápia
SG10202012080UA (en) * 2016-06-03 2021-01-28 Chemocentryx Inc Method of treating liver fibrosis
MX2021014356A (es) 2016-11-23 2022-11-24 Chemocentryx Inc Metodo para tratar glomeruloesclerosis segmentaria focal.
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
AU2018256406A1 (en) 2017-04-19 2019-10-17 Marengo Therapeutics, Inc. Multispecific molecules and uses thereof
CU24636B1 (es) 2017-05-02 2022-12-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP2020536919A (ja) 2017-10-11 2020-12-17 ケモセントリックス， インコーポレイテッド Ｃｃｒ２アンタゴニストによる巣状分節性糸球体硬化症の治療
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CA3085782A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
CA3085785A1 (en) * 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
CN112805014A (zh) * 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠的调配物
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
WO2020069372A1 (en) 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11965030B2 (en) 2018-12-24 2024-04-23 Sanofi Multispecific binding proteins with mutant fab domains
US20220146534A1 (en) * 2019-01-16 2022-05-12 Yeda Research And Development, Co., Ltd. Biomarkers for CNS Disease Modification
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
MX2021012163A (es) * 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
WO2020232127A1 (en) * 2019-05-13 2020-11-19 The Research Foundation For The State University Of New York Compositions and methods to block and bind ccr2 to modulate cellular function
MX2021015882A (es) * 2019-06-26 2022-04-18 Amunix Pharmaceuticals Inc Fragmentos de unión a antígeno egfr y composiciones que los comprenden.
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US20220025436A1 (en) * 2020-07-21 2022-01-27 Rutgers, The State University Of New Jersey Method and Kit For CCR2 Expression Profiling And Disease Stratification
CA3197167A1 (en) 2020-11-09 2022-05-12 He Xu Antibody drug conjugates
AU2022378899A1 (en) 2021-10-27 2024-03-07 Granite Bio Ag Antibodies targeting ccr2
CN114990073A (zh) * 2022-05-27 2022-09-02 河南农业大学 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
RU2194760C2 (ru) 1991-12-02 2002-12-20 Кор Терапьютикс, Инк. Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999045031A2 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) * 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AP1590A (en) 1998-12-23 2006-03-14 Pfizer Human monoclonal antibodies to CTLA-4.
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
WO2003048083A2 (en) 2001-11-30 2003-06-12 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
WO2003066830A2 (en) * 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
US7202343B2 (en) 2002-08-19 2007-04-10 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
ATE469969T1 (de) 2002-09-12 2010-06-15 Chemo Sero Therapeut Res Inst Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon
MXPA06000176A (es) 2003-12-10 2006-06-27 Millennium Pharm Inc Anticuerpos anti-ccr2 humanizados y sus metodos de uso.
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
WO2006085961A2 (en) 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
KR20080044360A (ko) 2004-07-30 2008-05-20 화이자 프로덕츠 인코포레이티드 Ｃｃｒ2 매개 질병 또는 장애의 치료방법
WO2008060783A2 (en) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis

Also Published As

Publication number Publication date
WO2010021697A3 (en) 2010-09-16
AU2009283199B2 (en) 2015-08-13
MY160892A (en) 2017-03-31
RU2547595C2 (ru) 2015-04-10
KR20110057166A (ko) 2011-05-31
KR101772706B1 (ko) 2017-08-29
IL211284A (en) 2017-07-31
CA2734578C (en) 2019-03-12
US20140342450A1 (en) 2014-11-20
RU2011110169A (ru) 2012-09-27
NZ591471A (en) 2012-08-31
SG193216A1 (en) 2013-09-30
ES2658117T3 (es) 2018-03-08
US20110274696A1 (en) 2011-11-10
NO2321351T3 (xx) 2018-03-31
EP2321351B1 (en) 2017-11-01
AU2009283199A8 (en) 2011-06-16
JP2012500020A (ja) 2012-01-05
CN102239180A (zh) 2011-11-09
AU2009283199A1 (en) 2010-02-25
CO6351802A2 (es) 2011-12-20
EP2321351A2 (en) 2011-05-18
US9238691B2 (en) 2016-01-19
BRPI0916973A2 (pt) 2016-07-26
WO2010021697A2 (en) 2010-02-25
PE20110774A1 (es) 2011-10-13
HK1163134A1 (en) 2012-09-07
CA2734578A1 (en) 2010-02-25
MX2011001911A (es) 2011-07-04
CN102239180B (zh) 2014-12-31
US8710191B2 (en) 2014-04-29
IL211284A0 (en) 2011-04-28
ZA201101047B (en) 2012-04-25
JP5685535B2 (ja) 2015-03-18
DK2321351T3 (en) 2017-12-18

Similar Documents

Publication Publication Date Title
HK1163134A1 (en) Antibodies to ccr2 ccr2
HK1217711A1 (zh) 特異於鈣粘素- 的抗體
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
ZA201102119B (en) Improved antibody libraies
GB0909906D0 (en) Antibodies
EP2220247A4 (en) ANTIBODIES DIRECTED AGAINST LRP6
ZA201003876B (en) Antibodies to gdf8 as uses thereof
EP3064512C0 (en) ANTIBODIES AGAINST CLDN6
GB0821100D0 (en) Antibodies
ZA201007955B (en) Anti-cxcr4 antibodies
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
EP2212431A4 (en) ANTI-IREM-1 ANTIBODIES
ZA201006099B (en) Anti-tyrp1 antibodies
PL2488554T3 (pl) Przeciwciała przeciw epha3
GB0920324D0 (en) Antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0911770D0 (en) Antibody
GB0801891D0 (en) Brekkie to go range
GB0823562D0 (en) Antibodies